| Hazard Information | Back Directory | [Uses]
Lomtegovimab (BI 767551) is a human anti-SARS-COV-2 spike glycoprotein monoclonal antibody. Lomtegovimab binds and neutralizes SARS-CoV-2. Lomtegovimab shows antiviral efficacy. Lomtegovimab has the potential for the research of COVID-19[1][2]. | [in vivo]
Lomtegovimab (40 mg/kg; i.p. or i.n.; once; three days before infection) protects hACE2-transduced mice from infection with SARS-CoV-2[2]. | Animal Model: | BALB/c mice (Ad_ACE2-mCherry)[2] | | Dosage: | 40 mg/kg | | Administration: | I.p. or I.n.; once; three days before infection | | Result: | Led to a complete neutralization of infectious SARS-CoV-2 and slightly reduced amounts of viral RNA in the lungs of treated animals. |
| [References]
[1] Halwe S, et al. Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection. Viruses. 2021 Jul 29;13(8):1498. DOI:10.3390/v13081498 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|